Main Therapeutic Uses

Heviran is an antiviral medication primarily used to manage infections caused by the herpes simplex virus (HSV) and the varicella-zoster virus (VZV). The active substance, aciclovir, works by inhibiting the replication of viral DNA, which helps the body control the spread of the infection.

Herpes Simplex Virus (HSV) Infections

The medication is frequently used for the treatment of skin and mucous membrane infections caused by HSV, which include:

• Labial Herpes: Commonly known as cold sores, affecting the lips and face.
• Genital Herpes: Treatment of primary outbreaks and management of recurrent episodes.
• Recurrence Prevention: Long-term administration in individuals with frequent relapses to reduce the number and severity of future outbreaks.

Varicella-Zoster Virus (VZV) Infections

Heviran is also indicated for conditions caused by the varicella-zoster virus:

• Chickenpox (Varicella): Used to reduce the duration and severity of the viral infection.
• Shingles (Herpes Zoster): Treatment of the painful skin rash caused by the reactivation of the virus in adults.

Benefits of Treatment

The primary clinical benefit of Heviran is its ability to interfere specifically with viral cells without significantly affecting healthy human cells. When initiated at the first signs of infection, the medication can provide several advantages:

• Reduction in Viral Shedding: Lowering the amount of active virus present on the skin or mucous membranes.
• Symptom Management: Shortening the period of pain, itching, and tingling associated with viral lesions.
• Faster Healing: Accelerating the crusting and disappearance of blisters and sores.
• Prevention of Complications: Reducing the risk of the virus spreading to other parts of the body or leading to secondary issues, such as post-herpetic neuralgia in shingles patients.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Heviran — Official Regulatory Information

Contraindicated Populations

The medicine must NOT be used by patients who have a known, clinically significant hypersensitivity reaction to aciclovir, to its related drug valaciclovir, or to any of the product’s non-active components. Tablet formulations are also contraindicated in patients with rare hereditary problems of galactose intolerance or glucose-galactose malabsorption.

Age-Related Eligibility

Heviran is approved for use in adults and children, including infants, though dose requirements are often adjusted based on age and body weight. Use in older adults (geriatrics) requires careful consideration due to the high likelihood of age-related reduced renal function.

Condition-Specific Restrictions

Classification	Population/Condition	Restriction Basis
Conditional Use	Reduced Renal Function	Aciclovir is cleared by the kidneys, so use is restricted and mandatory dose adjustment is required to mitigate risk [Source 1.5, 2.1].
Caution Required	Underlying Neurological Abnormalities	Must be used with caution, as these patients are at increased risk of developing neurological adverse effects [Source 2.1].
Conditional Use	Pregnancy & Lactation	Use is permitted only when the potential benefits outweigh the possibility of unknown risks; aciclovir is detected in breast milk [Source 2.1, 1.3].

Connection to the overall eligibility profile:

Official regulatory documents define eligibility by establishing Hypersensitivity Status as the absolute contraindication for use. Renal Clearance Capability acts as the primary physiological constraint, requiring dose reduction and close monitoring in patients with reduced kidney function and in the elderly to manage the potential for accumulation and increased risk of effects on the nervous system.

Interactions with other medicines and products

Interaction scope

Medicinal product categories with documented interactions:

• Medicinal products that are eliminated via active renal tubular secretion.
• Medicinal products that are known to have nephrotoxic potential.

Specific interacting medicines (if explicitly listed):

• Probenecid
• Cimetidine
• Mycophenolate Mofetil

Mechanistic basis of interactions (only if stated in label):

• Pharmacokinetic Interaction (Renal Competition): Inhibition of, or competition for, active renal tubular secretion by the kidney [FDA Zovirax Label].
• Pharmacodynamic Interaction (Additive Toxicity): Additive risk of renal dysfunction when co-administered [EMA SmPC].

Timing-based interaction rules (if applicable):

• None documented. No mandatory dose separation is specified in primary regulatory labels.

Population-specific interaction notes (if applicable):

• Elderly Patients: Higher systemic exposure (AUC) is observed in older adults, requiring consideration due to age-related decline in renal function, which influences clearance [FDA Zovirax Label].

---

Resulting interaction structure

Official interaction statements:

• Co-administration of Probenecid causes a reduction in Aciclovir’s renal clearance, resulting in an officially documented increase in the mean plasma half-life and AUC.
• The co-administration of Mycophenolate Mofetil results in an officially documented increase in the plasma concentrations of both the antiviral agent and the active metabolite of MMF.
• Co-administration with other potentially nephrotoxic medicinal products is associated with a formally documented increased risk of renal impairment.
• No clinically significant interaction is documented in regulatory sources for co-administration with food or alcohol.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the product's interaction structure based on the drug's near-exclusive elimination by the kidneys. This defines a major pharmacokinetic interaction domain involving substances that compete for renal tubular secretion, thereby formally increasing systemic exposure. It also establishes a key pharmacodynamic interaction domain regarding the additive risk of renal dysfunction when co-administered with other medicinal products that affect kidney function.

Selective Activation by Viral Thymidine Kinase

The drug begins as an inactive molecule and its mechanism is intrinsically targeted to virus-infected cells. This specificity stems from its requirement to be initially phosphorylated by Viral Thymidine Kinase (TK), an enzyme produced by the herpes simplex and varicella-zoster viruses inside the infected cell. This process facilitates the initial conversion of the molecule into its active intermediate within the infected cell, which results in the selective inhibition of viral processes.

---

Obligate Termination of Viral DNA Synthesis

Once fully activated to its triphosphate form by host cellular enzymes, the molecule functions as a faulty building block that mimics the natural nucleotide, dGTP. It competitively inhibits and then becomes permanently incorporated into the growing viral DNA strand by the Viral DNA Polymerase. Because the incorporated drug lacks a critical hydroxyl group, it causes an immediate and irreversible halt (chain termination) to the DNA assembly process, which results in the abrupt cessation of the viral proliferation cascade.

---

Mechanism Limitations Against Latent and Resistant Virus

The mechanism is functionally constrained by the biological state of the virus. It cannot act against the dormant or latent virus because the necessary activating enzyme, Viral TK, is not being produced during the latent phase. Furthermore, the mechanism is rendered ineffective if the virus develops resistance, typically through mutations that eliminate or alter the Viral TK, preventing the initial drug activation required for the entire inhibitory cascade to proceed.

How Heviran (Aciclovir) is Used

The usage of aciclovir is strictly defined by the intended purpose and the patient's condition, with specific regimens for the drug's various formulations. The administration is provided through multiple official routes, including oral (tablets or suspension), topical (creams), and intravenous (IV) for systemic or severe infections.

Official Dosing and Scheduling Patterns

Usage patterns dictate that treatment should commence as early as possible—ideally at the first sign of an outbreak. Standardized dosing and frequency are crucial for proper administration.

Usage Context	Standard Adult Dose	Frequency and Duration
Acute Oral HSV	200 mg	Five times daily for 5 to 10 days
Oral Suppression	400 mg	Twice daily, reviewed periodically (e.g., up to 12 months)
Acute Oral Herpes Zoster	800 mg	Five times daily for 7 to 10 days
Intravenous (IV)	5 mg/kg or 10 mg/kg	Every 8 hours, for 5 to 10 days or longer

Oral forms of aciclovir may be taken with or without food. However, for all administration types, adequate hydration must be maintained to adhere to proper use guidelines. The IV powder requires reconstitution and must be administered by slow infusion over a period of at least one hour.

Population-Specific Use

Because the medicine is primarily eliminated through the kidneys, official instructions mandate dose reduction for patients with renal impairment. The dosing interval or total daily dose must be modified based on creatinine clearance, and older adults may require adjustment due to age-related decline in kidney function.

Research Evidence / Overview of Studies for Heviran

The research evidence for the active ingredient in Heviran, aciclovir, primarily comes from Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies help show what has been observed so far about the medicine in specific viral infections, focusing on changes in symptoms and clinical markers.

---

Evidence from Controlled Trials for Shingles (Herpes Zoster)

Research has explored the use of aciclovir in individuals with Shingles, a condition associated with periods of heightened symptoms like rash and nerve pain. Studies monitored the time required for rash healing and reported patterns where the measured duration was shorter in the group receiving the medication compared to the group receiving a placebo. Research highlights changes measured during the study period for acute pain, with some trials describing a difference in the measured duration of discomfort. Evidence related to long-term pain (Postherpetic Neuralgia or PHN) was mixed across studies; some findings describe patterns associated with a difference, while other trials reported no distinct difference compared to placebo.

Research for Managing Acute and Recurrent Genital Herpes

Aciclovir was evaluated in studies designed to manage Genital Herpes, a condition characterized by fluctuating or episodic manifestations. Studies focusing on acute episodes reported patterns showing a shorter measured time required for complete lesion resolution and for the local discomfort to subside. For recurrence prevention, long-term RCTs monitored the frequency of symptomatic outbreaks. Studies monitored the frequency of symptomatic outbreaks and reported patterns showing a difference in the rate of outbreaks during continuous administration compared to inactive control groups. However, this evidence does not determine whether an individual will respond similarly once the continuous therapy is stopped.

Research on Chickenpox (Varicella) and Severe Systemic Infections

The use of aciclovir in healthy children with Chickenpox was studied for outcomes related to the duration of fever and the overall severity of the rash. In studies among otherwise healthy children, the findings indicate a difference in the measured duration of fever during the study period. For severe systemic infections, such as Herpes Simplex Encephalitis, foundational research describes patterns where the survival rate was associated with differences when compared to previous standards of care. However, the data show variable long-term functional recovery patterns.

---

Evidence in Specific Populations and Research Gaps

Research has explored different populations, but data for certain groups remain insufficient. For neonatal infections (severe cases in infants), specific studies examined long-term follow-up and neurological outcomes, describing some patterns associated with differences in neurodevelopmental assessments in those receiving prolonged therapy. The lack of consistent findings regarding the influence on long-term pain after Shingles remains a key area of research uncertainty. Furthermore, comparative evidence is lacking for many head-to-head comparisons against newer, related antivirals in large, definitive trials.

Key Studies & References Does Treatment of Acute Herpes Zoster Prevent or Shorten Postherpetic Neuralgia? A Systematic Review of the Literature

Common questions about Heviran (FAQ)

---

Q: What should I do if I miss a dose of the medicine?

A: If a dose of Heviran is missed, the official patient information advises taking the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the standard recommendation is to skip the missed dose and return to the regular dosing schedule. It is important to note that a dose should never be doubled to make up for a missed one.

---

Q: What is the recommended maximum daily dose?

A: Official labeling indicates that the highest doses described for common adult treatments are typically used for infections such as herpes zoster, which can involve a dose of 800 mg taken five times per day. Overall, the appropriate dosing regimen is highly dependent on the condition being treated and is based on a patient's renal function, so individual dose requirements vary.

---

Q: What are the signs of an allergic reaction to aciclovir?

A: Signs of a serious allergic reaction, as described in regulatory documents, may include a rash, hives, or swelling of the face, lips, tongue, or throat. If these symptoms occur, or if there is difficulty breathing or swallowing, they warrant immediate medical attention, as they could indicate a severe reaction like anaphylaxis.

---

Q: Is Heviran safe to use during pregnancy?

A: According to the official product information, the use of Heviran during pregnancy is permitted only when the potential benefits are judged to outweigh the possible, though unknown, risks. Limited data from a pregnancy registry did not show an increased risk of birth defects. The decision to use this medicine while pregnant is typically made in consultation with a healthcare provider.

---

Q: How quickly does aciclovir start working?

A: Official regulatory documents advise that for the best results, treatment should be initiated as early as possible after the first signs or symptoms of the infection appear. However, the product information does not specify an exact timeframe for the onset of drug action or when symptom relief may begin.

---

Q: What are the most common side effects of Heviran?

A: Based on the frequency described in regulatory sources, the most common side effects (those occurring in 1 in 10 to 1 in 100 people) include headache, dizziness, nausea, vomiting, diarrhea, and abdominal pain. Other commonly documented effects are fatigue, fever, itching (pruritus), and rashes.

---

Q: How does Probenecid interact with Heviran?

A: Co-administration with the drug Probenecid is documented to reduce the rate at which Heviran is cleared by the kidneys. This official pharmacokinetic interaction causes an increase in the amount of Aciclovir in the bloodstream and prolongs the time it stays in the body (half-life).

---

Q: Will aciclovir stop the virus from coming back later?

A: Official information states that the medicine is not a cure for chronic viral conditions like genital herpes. While taking continuous suppressive therapy may prevent symptomatic outbreaks, regulatory data does not determine whether the medicine will prevent future recurrences or transmission once the continuous treatment is stopped.

---

Q: Can I drink alcohol while taking Heviran?

A: Official regulatory documents do not document a clinically significant interaction when Aciclovir is administered with alcohol. For specific advice related to your health conditions, always consult a healthcare professional.

How to Store and Dispose of Acyclovir (Heviran)

Storage and disposal must strictly adhere to official regulatory labeling to ensure product integrity and safety.

Storage Conditions

Acyclovir tablets require storage at Controlled Room Temperature (20 C to 25 C) and must be protected from moisture. The oral suspension should be stored between 15 C and 25 C. The dry powder for injection must be stored below 25 C or 30 C and protected from light. All forms must be stored in their original container and kept out of the sight and reach of children.

Stability and Handling

The reconstituted injection solution is stable for 12 hours at 25 C but should not be refrigerated to avoid precipitation.

Disposal Requirements

Unused or expired medicinal product must be disposed of according to local regulations and must not be discarded via wastewater or general household waste.